Statute Details
- Title: Health Products (Exemptions) Order 2016
- Act Code: HPA2007-S536-2016
- Legislative Type: Subsidiary legislation (SL)
- Authorising Act: Health Products Act (Cap. 122D), section 70
- Commencement: 1 November 2016
- Current Version Status: Current version as at 27 March 2026
- Enacting Authority: Health Sciences Authority (HSA)
- Key Provisions:
- Section 1: Citation and commencement
- Section 2: Definitions (therapeutic products, medical devices, CTGT products, and related regulations)
- Section 3: Exemptions are set out by category in Schedules 1–3
- Section 4: Revocation of earlier exemption orders
- Schedules:
- First Schedule: Exemptions relating to therapeutic products
- Second Schedule: Exemptions relating to medical devices
- Third Schedule: Exemptions relating to CTGT products
- Notable Amendments (from timeline):
- SL 536/2016 (original)
- Amended by S 321/2018 (1 June 2018)
- Amended by S 110/2021 (1 March 2021)
- Amended by S 435/2023 (31 Dec 2021; and 26 Jun 2023)
- Amended by S 804/2023 (18 Dec 2023)
What Is This Legislation About?
The Health Products (Exemptions) Order 2016 is a Singapore subsidiary law made under the Health Products Act. In plain terms, it creates a structured set of legal exemptions from certain regulatory requirements under the Health Products regulatory framework. The Order does not regulate health products directly in the way a licensing or registration statute would; rather, it identifies categories of health products and specifies when particular products (or classes of products) are exempted from specified controls.
The Order is especially important because it sits at the intersection of multiple regulatory regimes within Singapore’s health product law. The Health Products Act classifies health products into categories such as therapeutic products, medical devices, and CTGT products (cell, tissue and gene therapy products). This Order then provides the exemption map for each category by setting out exemptions in three separate schedules.
Practically, the Order helps manufacturers, importers, distributors, healthcare institutions, and legal advisers determine whether a particular product must comply with the full suite of regulatory obligations (for example, registration, licensing, or other compliance steps) or whether it falls within an exemption. This can affect product development timelines, regulatory strategy, and risk management.
What Are the Key Provisions?
Section 1 (Citation and commencement) is straightforward: it confirms the name of the Order and that it came into operation on 1 November 2016. For practitioners, this matters when assessing whether a product’s regulatory status is governed by the 2016 framework or by earlier exemption orders.
Section 2 (Definitions) provides the interpretive backbone for the Order. It defines key terms used throughout the exemption framework. Of particular note are the definitions of:
- “therapeutic product” — a health product categorised as a therapeutic product in the First Schedule to the Health Products Act;
- “medical device” — a health product categorised as a medical device in the First Schedule to the Health Products Act;
- “CTGT product” — a health product categorised as a cell, tissue or gene therapy product in the First Schedule to the Act; and
- the related regulatory instruments: “Therapeutic Products Regulations” (2016) and “CTGT Products Regulations” (2021).
The inclusion of CTGT-related definitions reflects the legislative evolution of Singapore’s health product regime. The Order was originally framed around therapeutic products and medical devices, but later amendments (notably the change effective 1 March 2021) incorporated CTGT products into the exemption architecture. For counsel, this is a reminder that exemption analysis must be done using the current version and the correct regulatory category.
Section 3 (Exemptions) is the core operative provision. It provides that:
- Section 3(1): exemptions relating to therapeutic products are set out in the First Schedule;
- Section 3(2): exemptions relating to medical devices are set out in the Second Schedule;
- Section 3(3): exemptions relating to CTGT products are set out in the Third Schedule.
This drafting approach is important legally. The Order itself does not list the exemptions in the body of the text; instead, it delegates the substantive exemption content to the schedules. As a result, legal advice typically requires a careful schedule-by-schedule review, including the precise wording of exemption conditions, scope limitations, and any procedural requirements (if the schedules cross-reference them).
Section 4 (Revocation) revokes earlier exemption orders: specifically, the Health Products (Medical Devices) (Exemption) Order 2012 and the Health Products (Medical Devices) (Exemption No. 2) Order 2012. This indicates that the 2016 Order is intended to be the consolidated and updated exemption instrument for the relevant categories. For practitioners, revocation provisions are crucial when dealing with historical compliance questions, audits, or enforcement matters that span multiple regulatory eras.
How Is This Legislation Structured?
The Order is structured in a conventional legislative format with a short enacting body and three schedules. The enacting body comprises:
- Sections 1–2: administrative and interpretive provisions (citation/commencement and definitions);
- Section 3: the operative “signposting” provision that directs readers to the schedules for the substantive exemptions; and
- Section 4: revocation of earlier exemption orders.
The substantive content is contained in the schedules:
- First Schedule: exemptions relating to therapeutic products;
- Second Schedule: exemptions relating to medical devices;
- Third Schedule: exemptions relating to CTGT products.
From a legal research perspective, this structure means that the practitioner’s workflow should be: (i) confirm the product category under the Health Products Act; (ii) consult the relevant schedule in the Exemptions Order; and (iii) cross-check any referenced regulations (Therapeutic Products Regulations 2016; CTGT Products Regulations 2021) and any conditions that may affect whether an exemption applies.
Who Does This Legislation Apply To?
The Order applies to persons and entities whose activities fall within Singapore’s regulation of health products—particularly where those products might otherwise be subject to regulatory requirements under the Health Products Act and its subsidiary regulations. While the Order itself is framed as an exemption instrument (rather than a licensing statute), its practical effect is to determine who must comply with the broader regulatory regime and who may be relieved from certain obligations.
In practice, the Order is relevant to:
- Manufacturers and sponsors of therapeutic products and CTGT products;
- Medical device manufacturers, importers, and distributors;
- Healthcare institutions and other entities that procure or handle health products; and
- Legal and regulatory compliance advisers assessing whether a product falls within an exemption.
Because the exemption schedules are category-specific, the applicability analysis is highly dependent on correct classification. Misclassification can lead to a mistaken belief that an exemption applies, which in turn can create regulatory and enforcement risk.
Why Is This Legislation Important?
The Health Products (Exemptions) Order 2016 is important because it provides the legal basis for carving out certain health products from the full regulatory burden. For regulated industries, exemptions can be the difference between a product being able to enter the market (or be used in specific contexts) without completing certain steps, versus needing to comply fully with registration, authorisation, or other statutory requirements.
From an enforcement and compliance standpoint, exemptions are typically interpreted strictly. Even where an exemption exists, practitioners should pay close attention to the scope and any conditions embedded in the schedule language. The Order’s schedule-based design means that counsel must read the exemption text carefully and confirm that the factual circumstances of the product match the exemption criteria.
Finally, the Order’s amendment history underscores that the exemption framework evolves alongside Singapore’s broader health product regulations. The incorporation of CTGT products (effective 1 March 2021) demonstrates that exemption analysis must be updated to reflect new regulatory categories and revised regulatory instruments. For ongoing compliance programmes, this means maintaining version control and ensuring that internal regulatory checklists track the current version “as at” the relevant date.
Related Legislation
- Health Products Act (Cap. 122D) — in particular section 70 (authorising power for this Order)
- Health Products (Therapeutic Products) Regulations 2016 (G.N. No. S 329/2016)
- Health Products (Cell, Tissue and Gene Therapy Products) Regulations 2021 (G.N. No. S 104/2021)
- Health Products (Medical Devices) (Exemption) Order 2012 (G.N. No. S 170/2012) — revoked
- Health Products (Medical Devices) (Exemption No. 2) Order 2012 (G.N. No. S 427/2012) — revoked
Source Documents
This article provides an overview of the Health Products (Exemptions) Order 2016 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.